Citigroup Maintains Buy on GoodRx Holdings, Raises Price Target to $5
Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ: GDRX ) with a Buy and raises the price target from $4 to $5.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.